Clinical trials: Early Esophageal Adenocarcinoma
Early Stage Esophageal Adenocarcinoma, Barrett Esophagus
Endoscopic Therapy of Early Cancer in Barretts Esophagus
This study is being done to see if treatment for esophageal cancer can be done using endoscopy for patients ineligible for surgical or radiological therapy.
- Trial name
- NCT00217087
- Testing
- Endoscopic Mucosal Resection, Photodynamic Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Esophageal Stenosis
Reduction in Symptomatic Esophageal Stricture Formation
Complete endoscopic resection of early neoplastic Barrett's Esophagus (BE) is a curative procedure. However, a significant proportion of patients develop symptomatic esophageal strictures following Complete Barrett's Eradication…
- Trial name
- NCT02039115
- Testing
- prednisone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- AdventHealth
Esophageal Cancer
Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)
The goal of this study is to evaluate the safety and efficacy of endoscopic spray cryotherapy using the CSA Medical, Inc. truFreeze System for patients with previously untreated early-stage cancer (T1a, N0, M0) who are ineligible…
- Trial name
- ICE-CANCER (NCT01868139)
- Testing
- Liquid nitrogen spray cryotherapy with the truFreeze device
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Maryland, Baltimore
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04089904
- Testing
- Pembrolizumab Injection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago